Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of OTR-8100 in advanced malignant tumors (mCRPC)
CTR20262930Phase 2Active
- Sponsor
- Alloray Biopharmaceutical
- Start
- Jul 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OTR-8100 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Alloray Biopharmaceutical. Started Jul 2026; status: active.
02
Drugs
OTR-8100
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20262930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262930.